Disease, Disability, and Injury Prevention and Control; Special Emphasis Panel: Musculoskeletal Research on Occupational Safety, Program Announcement (PA) 04-038, 1334 [E7-215]
Download as PDF
<![CDATA[
1334
Federal Register / Vol. 72, No. 7 / Thursday, January 11, 2007 / Notices
cprice-sewell on PROD1PC66 with NOTICES
Public comments are invited, and may
be filed with the Commission in either
paper or electronic form. All comments
should be filed as prescribed in the
ADDRESSES section above, and must be
received on or before the date specified
in the DATES section.
Analysis of Agreement Containing
Consent Order To Aid Public Comment
The Federal Trade Commission has
accepted, subject to final approval, an
agreement containing a consent order
from Goen Technologies Corp.,
Nutramerica Corp., TrimSpa, Inc., and
Alexander Szynalski a/k/a Alexander
Goen (together, ‘‘respondents’’).
The proposed consent order has been
placed on the public record for thirty
(30) days for receipt of comments by
interested persons. Comments received
during this period will become part of
the public record. After thirty (30) days,
the Commission will again review the
agreement and the comments received,
and will decide whether it should
withdraw from the agreement or make
final the agreement’s proposed order.
This matter involves the advertising
and promotion of TrimSpa Completely
Ephedra Free Formula X32 (‘‘TrimSpa
X32’’), a dietary supplement that,
according to its label, contains, among
other ingredients, Hoodia gordonii,
chromium, vanadium, glucomannan,
citrus naringine, glucosamine HCI,
cocoa extract, and green tea extract.
According to the FTC complaint,
respondents represented that TrimSpa
X32 causes rapid and substantial weight
loss; and that Hoodia gordonii—an
African appetite suppressant—in
TrimSpa X32 enables users to lose
substantial amounts of weight by
suppressing their appetite. The
complaint alleges that respondents
failed to have substantiation for these
claims. The proposed consent order
contains provisions designed to prevent
respondents from engaging in similar
acts and practices in the future.
Part I of the proposed order requires
respondents to have competent and
reliable scientific evidence
substantiating any claims that a covered
product or service causes rapid and
substantial weight loss or that the
Hoodia gordonii, or any other appetite
suppressant, in a covered product
enables users to lose substantial
amounts of weight by suppressing their
appetite. The provision further requires
that any such claim be true. A ‘‘covered
product or service’’ is defined as ‘‘any
dietary supplement, food, drug, or
device, or any health-related service or
program.’’ Part I.C. further requires that
future claims about the health benefits,
performance, efficacy, safety, or side
VerDate Aug<31>2005
15:52 Jan 10, 2007
Jkt 211001
effects of any covered product or service
be truthful and supported by competent
and reliable scientific evidence.
Part II of the proposed order provides
that the order does not prohibit
respondents from making
representations for any drug that are
permitted in labeling for the drug under
any tentative final or final Food and
Drug Administration (‘‘FDA’’) standard
or under any new drug application
approved by the FDA; representations
for any medical device that are
permitted in labeling under any new
medical device application approved by
the FDA; and representations for any
product that are specifically permitted
in labeling for that product by
regulations issued by the FDA under the
Nutrition Labeling and Education Act of
1990.
Part III provides for the payment of
$1,500,000 to the Commission.
Part IV of the proposed order requires
respondents to provide the Commission
with a list of all consumers who
respondents know purchased TrimSpa
X32 from March 1, 2003 through the
date of entry of this Order.
Parts V through IX require
respondents to keep copies of relevant
advertisements and materials
substantiating claims made in the
advertisements; to provide copies of the
order to certain of their personnel; to
notify the Commission of changes in
corporate structure (for the corporate
respondents) and changes in
employment (for the individual
respondent) that might affect
compliance obligations under the order;
and to file compliance reports with the
Commission. Part X provides that the
order will terminate after twenty (20)
years under certain circumstances.
The purpose of this analysis is to
facilitate public comment on the
proposed order, and it is not intended
to constitute an official interpretation of
the agreement and proposed order or to
modify in any way their terms.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
By direction of the Commission, with
Commissioner Rosch recused.
Donald S. Clark,
Secretary.
[FR Doc. E7–206 Filed 1–10–07; 8:45 am]
Health Resources and Services
Administration
BILLING CODE 6750–01–P
AGENCY:
PO 00000
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control; Special
Emphasis Panel: Musculoskeletal
Research on Occupational Safety,
Program Announcement (PA) 04–038
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting of the
aforementioned Special Emphasis
Panel.
Time and Date: 1 p.m.–2 p.m., January 29,
2007 (Closed).
Place: National Institute for Occupational
Safety and Health (NIOSH), CDC, 626
Cochrans Mill Road, Pittsburgh, PA 15236.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the review, discussion, and
evaluation of a research grant application in
response to ‘‘Musculoskeletal Research on
Occupational Safety,’’ PA 04–038.
For Further Information Contact: George
Bokosh, Scientific Review Administrator,
NIOSH, 626 Cochrans Mill Road, Pittsburgh,
PA 15236, telephone (412) 386–6465.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: January 4, 2007.
Elaine Baker,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E7–215 Filed 1–10–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Advisory Committee on Organ
Transplantation
Health Resources and Services
Administration (HRSA), HHS.
ACTION: Notice of ACOT Meeting to be
held by Conference Call.
SUMMARY: The Advisory Committee on
Organ Transplantation (ACOT) will be
conducting a conference call to discuss
Frm 00026
Fmt 4703
Sfmt 4703
E:\FR\FM\11JAN1.SGM
11JAN1
]]>Agencies
[Federal Register Volume 72, Number 7 (Thursday, January 11, 2007)]
[Notices]
[Page 1334]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-215]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control; Special
Emphasis Panel: Musculoskeletal Research on Occupational Safety,
Program Announcement (PA) 04-038
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting of the aforementioned Special
Emphasis Panel.
Time and Date: 1 p.m.-2 p.m., January 29, 2007 (Closed).
Place: National Institute for Occupational Safety and Health
(NIOSH), CDC, 626 Cochrans Mill Road, Pittsburgh, PA 15236.
Status: The meeting will be closed to the public in accordance
with provisions set forth in section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters To Be Discussed: The meeting will include the review,
discussion, and evaluation of a research grant application in
response to ``Musculoskeletal Research on Occupational Safety,'' PA
04-038.
For Further Information Contact: George Bokosh, Scientific
Review Administrator, NIOSH, 626 Cochrans Mill Road, Pittsburgh, PA
15236, telephone (412) 386-6465.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: January 4, 2007.
Elaine Baker,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. E7-215 Filed 1-10-07; 8:45 am]
BILLING CODE 4163-18-P
